Kora Saúde Participações Full Year 2024 Earnings: R$2.08 loss per share (vs R$2.17 loss in FY 2023)

Simply Wall St

April 03, 2025

Kora Saúde Participações (BVMF:KRSA3) Full Year 2024 Results

Key Financial Results

Revenue: R$2.27b (flat on FY 2023).
Net loss: R$159.6m (loss narrowed by 4.8% from FY 2023).
R$2.08 loss per share (improved from R$2.17 loss in FY 2023).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

earnings-and-revenue-growth — BOVESPA:KRSA3 Earnings and Revenue Growth April 3rd 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Kora Saúde Participações Earnings Insights

Looking ahead, revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Healthcare industry in Brazil.

Performance of the Brazilian Healthcare industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

Be aware that Kora Saúde Participações is showing 1 warning sign in our investment analysis that you should know about...

The New Payments ETF Is Live on NASDAQ:

Money is moving to real-time rails, and a newly listed ETF now gives investors direct exposure. Fast settlement. Institutional custody. Simple access.

Explore how this launch could reshape portfolios

Valuation is complex, but we're here to simplify it.

Discover if Kora Saúde Participações might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.